The Indianapolis-based CDMO has ordered RoSS.FILL CGT to fill lentiviral vectors into small single-use bags. Specially designed for cell and gene therapies, RoSS.FILL CGT is an automated cGMP-compliant filling and filtration platform to dispense small to medium-sized volumes of highly valuable drug substances into multiple small single-use bags. The technology will be supplied to Genezen’s facility by the end of 2021.
Commenting on the announcement, newly appointed Genezen CEO, Ray Kaczmarek added: "It’s an exciting time to announce this agreement with SUSupport as Genezen makes significant strides towards the completion of our new multiphase 75,000+ square foot cGMP lentiviral and retroviral vector production facility in early 2022. Our facility will deliver cGMP-compliant viral vector production and a full suite of complementary process development capabilities to support commercial readiness."
Growing expertise in cell and gene therapies
End-to-end process solutions from Single-Use Support have proven to be successful at laboratory but also commercial scale in the production of bulk drug substance. Its involvement in the production of COVID-19 vaccines and mAbs demonstrated that the industry relies on its portfolio ranging from protection of single-use bags, filling & draining, freezing & thawing, cold storage and shipping. The purchase from Genezen demonstrates once again the technologies’ flexibility and its applicability to different areas in Biopharma. Cell & gene therapies and upstream seed train intensification are such fields where customers can use solutions for different batch sizes and volumes while remaining independent from any single-use bag or bottle.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!